CHMP2A / BC2 (1-222, His-tag) Human Protein
CAT#: AR09253PU-N
CHMP2A / BC2 (1-222, His-tag) human recombinant protein, 0.1 mg
Need it in bulk or customized? Get a free quote |
CNY 9,910.00
货期*
详询
规格
Specifications
Product Data | |
Species | Human |
Expression Host | E. coli |
Expression cDNA Clone or AA Sequence |
MGSSHHHHHH SSGLVPRGSH MDLLFGRRKT PEELLRQNQR ALNRAMRELD RERQKLETQE KKIIADIKKM AKQGQMDAVR IMAKDLVRTR RYVRKFVLMR ANIQAVSLKI QTLKSNNSMA QAMKGVTKAM GTMNRQLKLP QIQKIMMEFE RQAEIMDMKE EMMNDAIDDA MGDEEDEEES DAVVSQVLDE LGLSLTDELS NLPSTGGSLS VAAGGKKAEA AASALADADA DLEERLKNLR RD
|
Tag | His-tag |
Predicted MW | 27.2 kDa |
Concentration | lot specific |
Purity | >90% by SDS - PAGE |
Buffer | Presentation State: Purified State: Liquid purified protein Buffer System: 20 mM Tris-HCl buffer (pH 8.0) containing 0.1 M NaCl 1 mM DTT, and 30% glycerol |
Preparation | Liquid purified protein |
Protein Description | Recombinant CHMP2A protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. |
Storage | Store undiluted at 2-8°C for up to two weeks or (in aliquots) at -20°C or -70°C for longer. Avoid repeated freezing and thawing. |
Stability | Shelf life: one year from despatch. |
Reference Data | |
RefSeq | NP_055268 |
Locus ID | 27243 |
UniProt ID | O43633 |
Cytogenetics | 19q13.43 |
Synonyms | CHMP2, BC-2, Vps2-1 |
Summary | CHMP2A belongs to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. These proteins are components of ESCRT-III (endosomal sorting complex required for transport III), a complex involved in degradation of surface receptor proteins and formation of endocytic multivesicular bodies (MVBs). Some CHMPs have both nuclear and cytoplasmic/vesicular distributions, and one such CHMP, CHMP1A (MIM 164010), is required for both MVB formation and regulation of cell cycle progression (Tsang et al., 2006 [PubMed 16730941]).[supplied by OMIM, Mar 2008] |
Protein Pathways | Endocytosis |
Documents
FAQs |
SDS |
Customer
Reviews
Loading...